Insider Transactions in Q4 2020 at Kronos Bio, Inc. (KRON)
Insider Transaction List (Q4 2020)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 10
2020
|
Norbert W Bischofberger PRESIDENT & CEO |
BUY
Grant, award, or other acquisition
|
Direct |
198,124
+50.0%
|
-
|
|
Dec 09
2020
|
Yasir B. Al Wakeel Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
72,422
+39.78%
|
-
|
|
Dec 09
2020
|
Jorge Di Martino Chief Medical Officer & VP |
BUY
Grant, award, or other acquisition
|
Direct |
133,937
+50.0%
|
-
|
|
Dec 09
2020
|
Christopher Dinsmore Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
91,110
+48.6%
|
-
|
|
Dec 09
2020
|
Barbara Kosacz COO & General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
69,824
+9.26%
|
-
|
|
Oct 14
2020
|
Norbert W Bischofberger PRESIDENT & CEO |
BUY
Conversion of derivative security
|
Indirect |
3,208,835
+34.92%
|
$51,341,360
$16.15 P/Share
|
|
Oct 14
2020
|
Norbert W Bischofberger PRESIDENT & CEO |
BUY
Open market or private purchase
|
Indirect |
95,500
+2.14%
|
$1,814,500
$19.0 P/Share
|
|
Oct 14
2020
|
Bischofberger Norbert W. & Inger A. Revocable Inter Vivos Trust > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
95,500
+2.14%
|
$1,814,500
$19.0 P/Share
|
|
Oct 14
2020
|
Bischofberger Norbert W. & Inger A. Revocable Inter Vivos Trust > 10% Shareholder |
BUY
Conversion of derivative security
|
Direct |
2,153,835
+14.81%
|
$34,461,360
$16.15 P/Share
|
|
Oct 14
2020
|
Yasir B. Al Wakeel Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
5,250
+12.36%
|
$99,750
$19.0 P/Share
|
|
Oct 14
2020
|
Christopher Dinsmore Chief Scientific Officer |
BUY
Open market or private purchase
|
Direct |
5,250
+50.0%
|
$99,750
$19.0 P/Share
|
|
Oct 14
2020
|
Barbara Kosacz COO & General Counsel |
BUY
Open market or private purchase
|
Direct |
5,250
+0.85%
|
$99,750
$19.0 P/Share
|
|
Oct 14
2020
|
Arie Belldegrun |
BUY
Conversion of derivative security
|
Indirect |
2,739,052
+31.1%
|
$43,824,832
$16.15 P/Share
|
|
Oct 14
2020
|
Rebecka Belldegrun Director |
BUY
Conversion of derivative security
|
Indirect |
423,738
+27.79%
|
-
|
|
Oct 14
2020
|
Joshua A Kazam |
BUY
Conversion of derivative security
|
Direct |
92,371
+45.0%
|
-
|
|
Oct 14
2020
|
Jakob Loven Director |
BUY
Conversion of derivative security
|
Indirect |
1,545,344
+29.93%
|
$24,725,504
$16.15 P/Share
|
|
Oct 14
2020
|
John C Martin Director |
BUY
Open market or private purchase
|
Indirect |
75,800
+3.74%
|
$1,440,200
$19.0 P/Share
|
|
Oct 14
2020
|
John C Martin Director |
BUY
Conversion of derivative security
|
Indirect |
1,876,564
+30.34%
|
$30,025,024
$16.15 P/Share
|
|
Oct 14
2020
|
Elena Ridloff |
BUY
Open market or private purchase
|
Direct |
2,630
+50.0%
|
$49,970
$19.0 P/Share
|
|
Oct 14
2020
|
David M Tanen |
BUY
Conversion of derivative security
|
Indirect |
339,355
+19.99%
|
$5,429,680
$16.15 P/Share
|
|
Oct 14
2020
|
David M Tanen |
BUY
Conversion of derivative security
|
Direct |
231,553
+38.92%
|
-
|
|
Oct 14
2020
|
Otello Stampacchia Director |
BUY
Open market or private purchase
|
Indirect |
450,000
+10.54%
|
$8,550,000
$19.0 P/Share
|
|
Oct 14
2020
|
Otello Stampacchia Director |
BUY
Conversion of derivative security
|
Indirect |
3,348,832
+30.31%
|
$53,581,312
$16.15 P/Share
|
|
Oct 14
2020
|
Omega Fund V, L.P. > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
450,000
+10.54%
|
$8,550,000
$19.0 P/Share
|
|
Oct 14
2020
|
Omega Fund V, L.P. > 10% Shareholder |
BUY
Conversion of derivative security
|
Direct |
3,348,832
+30.31%
|
$53,581,312
$16.15 P/Share
|